Following is a transcript of their remarks:
Rugo: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now at San Antonio this year we saw an update of the really interesting monarchE data, the adjuvant trial looking at abemaciclib versus not additional therapy combined with endocrine therapy in the adjuvant setting for 2 years in patients who have quite high-risk early-stage hormone receptor-positive, HER2-negative breast cancer.
Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
So today, in our first discussion, we re going to talk about immunotherapy. This generated great interest at San Antonio and, of course, at all of the major meetings today that discussed breast cancer this year in 2020. I think we saw updates on immunotherapy that are potentially practice-changing at ASCO and ESMO Breast Cancer and ESMO, and now at San Antonio. Jo, do you want to start
email article
In the 21 months since the FDA granted accelerated approval to atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for locally advanced or metastatic PD-L1 positive triple-negative breast cancer (TNBC), Halle Moore, MD, of Cleveland Clinic Taussig Cancer Center in Ohio, has seen a definite uptake in use of the regimen. At our institution we routinely check upfront for PD-L1 expression, and unless it is contraindicated or a patient is going on a clinical trial, we recommend the combination in eligible patients, Moore said.
Even in that small time since the approval of that first immunotherapy, the field has already seen changes.